MOLN — Molecular Partners AG

MOLN closed at $3.71 (-2.60%) on Oct 28, 2026. Float: 37.4M shares. Latest SEC filing: 6-K on Aug 25, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for MOLN in the TickerWise workspace.

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: CH
• Exchange: NASDAQ
• Employees: 158
• Website: https://www.molecularpartners.com

Latest SEC filings for MOLN

• 2026-08-256-K
• 2026-07-206-K
• 2026-06-24S-8
• 2026-06-016-K
• 2026-05-126-K
• 2026-05-016-K
• 2026-04-146-K
• 2026-03-306-K
• 2026-03-136-K
• 2026-03-126-K

Latest MOLN news

• 2026-10-29Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy Read article

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.